Master Framework For Relapse or Refractory Acute Myeloid Leukemia

NCT06459024 · tracked via the Priya Life Science Germany tracker

Sponsor

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase

Observational

Started

2024-06-28

Last updated

2026-08-14

Condition(s) studied

Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia Refractory

Investigational drug(s) / intervention(s)

Registration into the STREAM platform

Registration into the STREAM platform: All patients fulfilling eligibility criteria will be registered into the STREAM platform. Baseline and follow up information will be recorded for each patient enrolled. Each patient will be followed up according to normal clinical practice up to 4 years.

Study summary

This is an observational (non-interventional), prospective, cohort study that will collects data from patients diagnosed with relapsed or refractory acute myeloid leukemia afferent to the participanting clinical sites

Eligibility

Sex

ALL

Min age

6 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Patients with AML diagnosis according to WHO2022 or ICC2022 * Treatment failure (i.e. relapse, refractory or progression, including MRD) according to ELN2022 criteria * Participant or his/her legal representative is willing and able to give informed consent for participation in the study Exclusion Criteria: * Patients included in clinical trials may be enrolled except where otherwise specified in the experimental protocol.

Primary outcome measure(s)

The primary endpoint is to determine the overall survival of R/R AML patients — 8 years
Overall survival is defined as the time from R/R diagnosis to death due to any cause.

Trial sites (40)

Facility	City	Region	Status
University Hospital Aachen	Aachen	Germany	Recruiting
University Hospital Greifswald	Greifswald	Germany	Recruiting
University Hospital Halle	Halle	Germany	Recruiting
University Hospital of Rostock	Rostock	Germany	Recruiting
Policlinico Sant'Orsola-Malpighi	Bologna	BO	Recruiting
Ospedale "A. Perrino"	Brindisi	BR	Recruiting
ASST Spedali Civili	Brescia	BS	Recruiting
Azienda Ospedaliera S. Croce e Carle	Cuneo	CN	Recruiting
Ospedale Valduce	Como	CO	Recruiting
ASST Cremona	Cremona	CR	Recruiting
AOU Universitaria Arcispedale Sant'Anna	Ferrara	FE	Recruiting
IRCCS Ospedale Policlinico San Martino	Genova	GE	Recruiting
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico	Milan	MI	Recruiting
ASST Grande Ospedale Metropolitano Niguarda	Milan	MI	Recruiting
Azienda Ospedaliera Ospedali Riuniti Villa Sofia - Cervello	Palermo	PA	Recruiting
Presidio Ospedaliero "Santo Spirito"	Pescara	PE	Not Yet Recruiting
Ospedale Santa Maria della Misericordia	Perugia	PG	Recruiting
Ospedale Santa Maria delle Croci	Ravenna	RA	Recruiting
Fondazione Policlinico Tor Vergata	Roma	RM	Recruiting
Policlinico Umberto I	Roma	RM	Recruiting
Policlinico Universitario Fondazione Agostino Gemelli	Roma	RM	Recruiting
Ospedale Sant'Andrea	Roma	RM	Recruiting
Ospedale infermi di Rimini	Rimini	RN	Recruiting
AOU San Giovanni di Dio e Ruggi d'Aragona	Salerno	SA	Recruiting
AOU Città della Salute e della Scienza di Torino	Torino	TO	Recruiting
AO Ordine Mauriziano	Torino	TO	Recruiting
IOV Istituto Oncologico Veneto	Castelfranco Veneto	TV	Recruiting
ASST Valle Olona	Busto Arsizio	VA	Recruiting
Azienda Ospedaliero Universitaria Delle Marche	Ancona	Italy	Not Yet Recruiting
AOU Careggi	Florence	Italy	Recruiting
IRST Istituto Romagnolo per lo Studio dei Tumori Dino Amadori	Meldola	Italy	Recruiting
Azienda Ospedaliera di Rilievo Nazionale Antonio Cardarelli	Naples	Italy	Recruiting
Azienda Ospeldaliera Universitaria Federico II	Naples	Italy	Not Yet Recruiting
AOU Maggiore della Carità	Novara	Italy	Recruiting
Azienda Ospedale-Università Padova	Padova	Italy	Not Yet Recruiting
Ospedale San Bortolo	Vicenza	Italy	Recruiting
The Hospital of Lithuanian University of Health Sciences Kauno Klinikos	Kaunas	Lithuania	Recruiting
University Clinical Center in Gdańsk	Gdansk	Poland	Recruiting
Fundeni Clinical Institute	Bucharest	Romania	Recruiting
University Hospital La Fe	Valencia	Spain	Recruiting

More Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS trials in Germany

IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia. Recruiting

Other trials for the same condition

Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (1b Dose Expansion) Recruiting

An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06459024 on ClinicalTrials.gov ↗ ← All trials in Germany